Syros Pharmaceuticals, Inc.
DelistedCIK 1556263fmd_1YBH35E1ZANDHX1EVVPTA7FGMMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2024, 40 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 2 | 2 | 15 | 23 | 15 | 10 |
| Research and development | 11 | 24 | 38 | 42 | 50 | 58 | 76 | 100 | 112 | 108 |
| Total operating expenses | 13 | 30 | 48 | 56 | 66 | 80 | 97 | 123 | 151 | 139 |
| Operating income | (13) | (30) | (48) | (55) | (64) | (78) | (82) | (99) | (136) | (129) |
| Interest expense | – | – | – | – | 0 | 0 | 2 | 4 | 4 | 5 |
| Interest and investment income | – | – | – | – | 2 | 2 | 0 | 0 | 2 | 7 |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | 2 | 2 | – | – | – | – |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (13) | (30) | (48) | (54) | (62) | (75) | (84) | (87) | (95) | (165) |
| Net income to common shareholders | (16) | (35) | (51) | (54) | (62) | (75) | (84) | (87) | (95) | (165) |